(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 2.42% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Viatris's revenue in 2026 is $14,562,600,000.On average, 13 Wall Street analysts forecast VTRS's revenue for 2026 to be $17,387,935,676,874, with the lowest VTRS revenue forecast at $16,617,001,819,926, and the highest VTRS revenue forecast at $18,015,629,557,380. On average, 12 Wall Street analysts forecast VTRS's revenue for 2027 to be $17,727,985,051,842, with the lowest VTRS revenue forecast at $16,753,254,480,444, and the highest VTRS revenue forecast at $18,636,336,121,962.
In 2028, VTRS is forecast to generate $18,259,021,062,066 in revenue, with the lowest revenue forecast at $17,024,595,248,826 and the highest revenue forecast at $19,381,649,820,522.